Live
Read now

Gennao Bio

This is the default server vhost

StageSeries B
Raised$55.99M
Founded2020
Employees6
LocationHopewell, NJ

About

Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and systemically deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells, including mRNA, synthetic RNA, DNA, si-RNA, ASOs and gene-editing molecules. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.

Founders

  • Peter Glazer
  • Elias Quijano
  • Stephen Squinto
  • Bruce Turner

Investors

OrbiMedLogos CapitalSurveyor CapitalCureDuchenne Ventures

News

Browse similar startups

Related startups

Profile updated Jul 29, 2026. Sources: gennao.com

ClinAdsby ClinsightBuilt for clinics

Your clinic’s marketing team, powered by AI.

On-brand ads, SEO, and social campaigns in one place.

Generate your first clinic ad for free
Clincyby ClinsightBuilt for practices

Get more revenue from the patients you already have.

Voice and SMS that follow up until lapsed patients are back on the schedule.

Book a Clincy call
DDS RecruitPowered by ClinsightDental recruiting

Your practice’s fractional recruiting team.

Dental-only search, run end to end, with placements guaranteed for a year.

Find your next hire